Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy

Cherry T. Thomas, Patrick T. Bradshaw, Bradley H Pollock, James E. Montie, Jeremy M G Taylor, Howard D. Thames, Patrick W. McLaughlin, David A. DeBiose, David H. Hussey, Richard L. Wahl

Research output: Contribution to journalReview article

97 Citations (Scopus)

Abstract

Purpose: We evaluated the prognostic significance of indium-111 ( 111In)-capromab pendetide imaging for patients with prostate cancer who underwent salvage radiotherapy (RT) for recurrent disease after prostatectomy. Patients and Methods: Records were reviewed for all men who underwent 111In-capromab pendetide imaging at a single institution from February 1997 through December 1999. We identified 30 eligible men who were radiographically negative for metastatic disease, who had increasing serum prostate-specific antigen (PSA) after primary radical prostatectomy, and who received salvage RT. Clinical interpretations of indium monoclonal antibody (In-mab) scan results were compared with postsalvage RT PSA response. Results: Using an American Society of Therapeutic Radiation and Oncology definition of PSA failure, in men with a positive scan in at least one location (n = 14), the cumulative 2-year PSA control after salvage RT was 0.38 ± 0.13 (± SE) compared with 0.31 ± 0.13 for men with a normal antibody scan in and outside the prostate fossa (n = 15; proportional hazard ratio [PHR] = 1.32; 95% confidence interval [CI], 0.52 to 3.36). For men with a positive antibody scan limited to the prostate fossa (n = 9), PSA control at 2 years was 0.13 ± 0.12 (PHR 1.77; 95% CI, 0.65 to 4.85). The 2-year probability of PSA control after salvage RT for men with positive scan results outside the prostate bed irrespective of In-mab findings in the prostate fossa (n = 5) was 0.60 ± 0.22 (PHR 0.81; 95% CI, 0.17 to 3.78). Conclusion: In contrast to previous reports, for patients with postprostatectomy biochemical relapse who received salvage RT, presalvage RT In-mab scan findings outside the prostate fossa were not predictive of biochemical control after RT.

Original languageEnglish (US)
Pages (from-to)1715-1721
Number of pages7
JournalJournal of Clinical Oncology
Volume21
Issue number9
DOIs
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Radioimmunodetection
Salvage Therapy
Indium
Prostatectomy
Radiotherapy
Prostate-Specific Antigen
Prostate
Monoclonal Antibodies
Confidence Intervals
Radiation Oncology
Capromab Pendetide
Antibodies
Prostatic Neoplasms
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. / Thomas, Cherry T.; Bradshaw, Patrick T.; Pollock, Bradley H; Montie, James E.; Taylor, Jeremy M G; Thames, Howard D.; McLaughlin, Patrick W.; DeBiose, David A.; Hussey, David H.; Wahl, Richard L.

In: Journal of Clinical Oncology, Vol. 21, No. 9, 01.05.2003, p. 1715-1721.

Research output: Contribution to journalReview article

Thomas, Cherry T. ; Bradshaw, Patrick T. ; Pollock, Bradley H ; Montie, James E. ; Taylor, Jeremy M G ; Thames, Howard D. ; McLaughlin, Patrick W. ; DeBiose, David A. ; Hussey, David H. ; Wahl, Richard L. / Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 9. pp. 1715-1721.
@article{7dd24aced93b4e048d6bec2a5460295b,
title = "Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy",
abstract = "Purpose: We evaluated the prognostic significance of indium-111 ( 111In)-capromab pendetide imaging for patients with prostate cancer who underwent salvage radiotherapy (RT) for recurrent disease after prostatectomy. Patients and Methods: Records were reviewed for all men who underwent 111In-capromab pendetide imaging at a single institution from February 1997 through December 1999. We identified 30 eligible men who were radiographically negative for metastatic disease, who had increasing serum prostate-specific antigen (PSA) after primary radical prostatectomy, and who received salvage RT. Clinical interpretations of indium monoclonal antibody (In-mab) scan results were compared with postsalvage RT PSA response. Results: Using an American Society of Therapeutic Radiation and Oncology definition of PSA failure, in men with a positive scan in at least one location (n = 14), the cumulative 2-year PSA control after salvage RT was 0.38 ± 0.13 (± SE) compared with 0.31 ± 0.13 for men with a normal antibody scan in and outside the prostate fossa (n = 15; proportional hazard ratio [PHR] = 1.32; 95{\%} confidence interval [CI], 0.52 to 3.36). For men with a positive antibody scan limited to the prostate fossa (n = 9), PSA control at 2 years was 0.13 ± 0.12 (PHR 1.77; 95{\%} CI, 0.65 to 4.85). The 2-year probability of PSA control after salvage RT for men with positive scan results outside the prostate bed irrespective of In-mab findings in the prostate fossa (n = 5) was 0.60 ± 0.22 (PHR 0.81; 95{\%} CI, 0.17 to 3.78). Conclusion: In contrast to previous reports, for patients with postprostatectomy biochemical relapse who received salvage RT, presalvage RT In-mab scan findings outside the prostate fossa were not predictive of biochemical control after RT.",
author = "Thomas, {Cherry T.} and Bradshaw, {Patrick T.} and Pollock, {Bradley H} and Montie, {James E.} and Taylor, {Jeremy M G} and Thames, {Howard D.} and McLaughlin, {Patrick W.} and DeBiose, {David A.} and Hussey, {David H.} and Wahl, {Richard L.}",
year = "2003",
month = "5",
day = "1",
doi = "10.1200/JCO.2003.05.138",
language = "English (US)",
volume = "21",
pages = "1715--1721",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy

AU - Thomas, Cherry T.

AU - Bradshaw, Patrick T.

AU - Pollock, Bradley H

AU - Montie, James E.

AU - Taylor, Jeremy M G

AU - Thames, Howard D.

AU - McLaughlin, Patrick W.

AU - DeBiose, David A.

AU - Hussey, David H.

AU - Wahl, Richard L.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Purpose: We evaluated the prognostic significance of indium-111 ( 111In)-capromab pendetide imaging for patients with prostate cancer who underwent salvage radiotherapy (RT) for recurrent disease after prostatectomy. Patients and Methods: Records were reviewed for all men who underwent 111In-capromab pendetide imaging at a single institution from February 1997 through December 1999. We identified 30 eligible men who were radiographically negative for metastatic disease, who had increasing serum prostate-specific antigen (PSA) after primary radical prostatectomy, and who received salvage RT. Clinical interpretations of indium monoclonal antibody (In-mab) scan results were compared with postsalvage RT PSA response. Results: Using an American Society of Therapeutic Radiation and Oncology definition of PSA failure, in men with a positive scan in at least one location (n = 14), the cumulative 2-year PSA control after salvage RT was 0.38 ± 0.13 (± SE) compared with 0.31 ± 0.13 for men with a normal antibody scan in and outside the prostate fossa (n = 15; proportional hazard ratio [PHR] = 1.32; 95% confidence interval [CI], 0.52 to 3.36). For men with a positive antibody scan limited to the prostate fossa (n = 9), PSA control at 2 years was 0.13 ± 0.12 (PHR 1.77; 95% CI, 0.65 to 4.85). The 2-year probability of PSA control after salvage RT for men with positive scan results outside the prostate bed irrespective of In-mab findings in the prostate fossa (n = 5) was 0.60 ± 0.22 (PHR 0.81; 95% CI, 0.17 to 3.78). Conclusion: In contrast to previous reports, for patients with postprostatectomy biochemical relapse who received salvage RT, presalvage RT In-mab scan findings outside the prostate fossa were not predictive of biochemical control after RT.

AB - Purpose: We evaluated the prognostic significance of indium-111 ( 111In)-capromab pendetide imaging for patients with prostate cancer who underwent salvage radiotherapy (RT) for recurrent disease after prostatectomy. Patients and Methods: Records were reviewed for all men who underwent 111In-capromab pendetide imaging at a single institution from February 1997 through December 1999. We identified 30 eligible men who were radiographically negative for metastatic disease, who had increasing serum prostate-specific antigen (PSA) after primary radical prostatectomy, and who received salvage RT. Clinical interpretations of indium monoclonal antibody (In-mab) scan results were compared with postsalvage RT PSA response. Results: Using an American Society of Therapeutic Radiation and Oncology definition of PSA failure, in men with a positive scan in at least one location (n = 14), the cumulative 2-year PSA control after salvage RT was 0.38 ± 0.13 (± SE) compared with 0.31 ± 0.13 for men with a normal antibody scan in and outside the prostate fossa (n = 15; proportional hazard ratio [PHR] = 1.32; 95% confidence interval [CI], 0.52 to 3.36). For men with a positive antibody scan limited to the prostate fossa (n = 9), PSA control at 2 years was 0.13 ± 0.12 (PHR 1.77; 95% CI, 0.65 to 4.85). The 2-year probability of PSA control after salvage RT for men with positive scan results outside the prostate bed irrespective of In-mab findings in the prostate fossa (n = 5) was 0.60 ± 0.22 (PHR 0.81; 95% CI, 0.17 to 3.78). Conclusion: In contrast to previous reports, for patients with postprostatectomy biochemical relapse who received salvage RT, presalvage RT In-mab scan findings outside the prostate fossa were not predictive of biochemical control after RT.

UR - http://www.scopus.com/inward/record.url?scp=0037797284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037797284&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.05.138

DO - 10.1200/JCO.2003.05.138

M3 - Review article

VL - 21

SP - 1715

EP - 1721

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -